Form D · Pharmaceuticals
858 Therapeutics, Inc.
San Diego, CA · CIK 0001806356
Offering snapshot reported Jul 11, 2024 · SEC filing
- Reported sold
- $25.2M Offering amount: $50.4M
- Investors reported
- 12 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 26, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 11, 2024 | Initial | $25,175,501 | No comparison | 12 | SEC filing |
| May 18, 2021 | Initial | $20,000,001 | No comparison | Not reported | SEC filing |
| Mar 11, 2020 | Initial | $20,056,095 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-518431
Source: Form D, filed Jul 11, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Ali Behbahani | Director |
| Katherine Bell Mc Guinn | Executive |
| Bradley J. Bolzon | Director |
| Jane Huang | Director |
| Stafford Jeffrey | Director, Executive |
| Monal Mehta | Director |
| Clare Ozawa | Director |
| Carlo Rizzuto | Director |
| Jeffrey A. Stafford | Director, Executive |
| James Veal | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
3115 Merryfield Row Suite 110
San Diego, CA, 92121
San Diego, CA, 92121